768 results about "Cell free" patented technology

A method and system for determining one or more sources of a cell free deoxyribonucleic acid (cfDNA) test sample from a test subject. The cfDNA test sample contains a plurality of deoxyribonucleic acid (DNA) molecules with numerous CpG sites that may be methylated or unmethylated. A trained deconvolution model comprises a plurality of methylation parameters, including a methylation level at each CpG site for each source, and a function relating a sample vector as input and a source of origin prediction as output. The method generates a test sample vector comprising a site methylation metric relating to DNA molecules from the test sample that are methylated at that CpG site. The method inputs the test sample vector into the trained deconvolution model to generate a source of origin prediction indicating a predicted DNA molecule contribution of each source.

There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.

This invention provides an in vitro cell-free protein synthesis system, its reagent kit, and its applications, belonging to the field of protein synthesis technology. This invention improves an in vitro cell-free protein synthesis system based on Kluyveromyces lactis by adding exogenous L-arabinose, significantly enhancing the system's protein synthesis capacity. Furthermore, it provides a more efficient and higher-throughput in vitro protein synthesis reagent kit and a method for synthesizing exogenous proteins. The improvements provided by this invention can be achieved without molecular modification, are simple and convenient to operate, and save costs.

Provided herein are methods of cell-free protein synthesis, optimised cell-free protein synthesis (CFPS) reagents for the expression of eukaryotic proteins and methods for optimising CFPS reagents to increase protein expression yields for mammalian proteins and subsequent expression in cells. The methods are applicable to protein expression on a microfluidic device having hydrophobic surfaces by merging droplets on the device in order to screen a selection of expression compositions in parallel and then identify the optimum conditions for producing the stable folded protein in a cell-based system.

The present disclosure relates to the seminal discovery of a generation and use of genetically engineered Vibrio sp. Provided is the use of the genetically engineered bacteria for the construction, maintenance, manipulation, and / or propagation of DNA constructs; protein expression; protein secretion; vectors and other metabolic tools; metabolic engineering; expression of cellular extracts for cell-free biology; shuttle vectors; cloning vectors; and for synthetic biology applications. The disclosure also relates to the use of the replication machinery of Vibrio sp. as a cloning or expression vector for replication of recombinant DNA constructs. The disclosure also relates to methods of use of the above.

The present disclosure includes a method of comprising (a) obtaining cell-free DNA (cfDNA) from a sample from a subject; (b) selectively enriching subsets of the cfDNA from (a) or derivatives therefrom having one or more target regions to obtain enriched DNA, wherein the target regions are differentially methylated in cancer; (c) sequencing the enriched DNA from (b) to obtain sequence reads; and (d) partitioning a plurality of the sequence reads into two or more groups based on their methylation status and determining the fragment length distribution of the sequence reads in at least one of the groups.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

The invention discloses high-purity recombinant collagen as well as a preparation method and application thereof, the recombinant collagen is composed of a recombinant collagen monomer, and the recombinant collagen monomer has an amino acid sequence as shown in any one of SEQ ID NO: 1-22. According to the present invention, the easy-to-break site and the hydrophobicity of the collagen are optimized, such that the obtained recombinant collagen monomer and the prepared recombinant collagen have characteristics of high cell activity (adhesion, migration and proliferation), high triple helix structure stability, high purity, no cytotoxicity, large-scale production, and production cost reduction.

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.

The application provides an in-vitro cell-free protein synthesis system and kit containing exogenous magnesium ions and application thereof, including a D2P system (DNA-to-Protein system) and an mR2P system (mRNA-to-Protein system), and belongs to the technical field of protein synthesis. The in-vitro cell-free protein synthesis system containing exogenous magnesium ions adopts magnesium aspartate as a novel magnesium ion source, and especially in a eukaryotic cell-free system, compared with a traditional magnesium ion source, can significantly improve the protein synthesis efficiency and protein expression amount. A more efficient and higher-throughput in-vitro protein synthesis kit and a synthesis method of exogenous proteins are also provided, and the kit has the advantages of simplicity, convenience and low cost.

The present invention discloses an antimicrobial peptide SETIT, which is derived from Paspalum vaginatum and has an amino acid sequence as shown in SEQ ID NO: 1. Also disclosed are its encoding DNA and expression system. The antimicrobial peptide SETIT of the present invention has an obvious inhibitory effect on Gram-positive, Gram-negative bacteria and fungi, has high antibacterial efficiency and good broad-spectrum. By expressing the antimicrobial peptide SETIT using an edible Kluyveromyces marxianus cell-free expression system, an edible millet antimicrobial peptide can be obtained.

Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.

Systems and methods for clustering in cell-free networks are described herein. A cluster of one or more base stations provides radio access network (RAN) functionality to a user equipment (UE) within the wireless communication system in a cell-free manner (e.g., without using a base-station-centric cell context, as in prior wireless communication systems). A cluster that is serving a UE comprises one or more connected base stations (cBSs) that actively serve the UE. A clustering control function (CCF) of the network establishes and maintains the cluster that is serving one or more UEs. Herein, messaging systems and messaging types used by the CCF, base station(s), and UE(s) within this cell-free context are discussed. Initial clustering methods used by a CCF to form a cluster for a UE are discussed. Further, clustering update methods used by a CCF to maintain / modify a cluster for a UE are discussed.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.

Provided herein are methods for replenishing dissolved gas to aqueous droplets on a digital microfluidic device. Provided herein are methods of cell-free protein synthesis, optimized cell-free protein synthesis (CFPS) reagents, and methods for optimizing CFPS reagents to increase protein expression yield. The method is suitable for protein expression on microfluidic devices having hydrophobic surfaces by circulating a fill fluid to introduce additional oxygen.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of the status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with lung cancer. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating a lung cancer.

A method for improving degradation efficiency of corn straw at low temperature comprises the steps that cell-free culture fluid PfCFs prepared from Pseudomonas fragi D12 participates in fermentation and degradation of the corn straw, the classification name of the strain D12 is Pseudomonas fragi D12, the strain D12 is preserved in China Center for Type Culture Collection, the preservation address is No. 299, 8th road, Wuchang District, Wuhan City, Hubei Province, China, and the preservation number is CGMCC NO. The preservation number is CCTCC (China Center For Type Culture Collection) NO: M2025126, and the preservation date is January 14, 2025. The acellular culture solution of the pseudomonas rubrassicae D12 can promote the growth of various normal-temperature bacteria and fungi functional bacteria at low temperature and improve the cold resistance of the functional bacteria, and CFS of the pseudomonas rubrassicae D12 also contains related enzymes capable of degrading lignin; at a low temperature, the PfCFs synchronously promotes the co-growth of bacteria bacillus subtilis and fungi Irpex lacteus, so that the degradation efficiency of the functional bacteria on lignocellulose in the corn straws is improved.

The present disclosure includes, among other things, methods, kits, and systems for determining HER2 status of cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of HER2 status of cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with cancer. In various embodiments a determined HER2 status is useful, e.g., in selecting treatment for and / or treating a cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer.

96 New PCT-Patent Application based on EP 24 186 635.9 Insempra GmbH Vossius Ref.: AG4141 PCT S3 Abstract The present invention relates to a linear double-stranded deoxyribonucleic acid (dsDNA) molecule comprising one or more Tus protein (Tus) binding site(s) at the 5'-terminus, one or more Lac repressor protein (LacI) binding site(s) at the 3'-terminus, and a segment comprising a DNA sequence of interest (DOI) between said Tus binding site(s) and said LacI binding site(s). The present invention further relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from the linear dsDNA molecule of the invention, and to an expression DNA cassette comprising a promoter, an RBS, a GOI encoding a POI, and one or more LacI binding site(s), wherein said expression cassette does not comprise a terminator sequence between the 3´ end of said GOI and said one or more LacI binding site(s). The present invention also relates to a non-naturally or naturally occurring RNA molecule as encoded by or transcribable / transcribed from said expression cassette. The present invention further relates to method of protecting a linear deoxyribonucleic acid (DNA) molecule from exonuclease degradation by adding one or more Tus binding site(s) at the first terminus of the DNA molecule and adding one or more LacI binding site(s) at the other terminus of the DNA molecule. The present invention further relates to a method of synthesizing a protein of interest (POI) in a cell- free protein synthesis (CFPS) reaction mixture by using the (ds)DNA and / or RNA molecules of the invention, and also to a cell-free biological system or CFPS reaction mixture comprising the (ds)DNA, expression cassette and / or RNA molecules of the invention.

Systems and methods for clustering in cell-free networks are described herein. A cluster of one or more base stations provides radio access network (RAN) functionality to a user equipment (UE) within the wireless communication system in a cell-free manner (e.g., without using a base-station-centric cell context, as in prior wireless communication systems). A cluster that is serving a UE comprises one or more connected base stations (cBSs) that actively serve the UE. A clustering control function (CCF) of the network establishes and maintains the cluster that is serving one or more UEs. Herein, messaging systems and messaging types used by the CCF, base station(s), and UE(s) within this cell-free context are discussed. Initial clustering methods used by a CCF to form a cluster for a UE are discussed. Further, clustering update methods used by a CCF to maintain / modify a cluster for a UE are discussed.

The invention relates to the technical field of medicines, and discloses pedunculoside temperature-sensitive injectable hydrogel as well as a preparation method and application thereof. Specifically, the invention provides application of the temperature-sensitive injectable hydrogel with the pedunculoside in preparation of the medicine for treating the cardiovascular diseases, and the temperature-sensitive injectable hydrogel with the pedunculoside comprises the pedunculoside, a lactic acid-glycolic acid copolymer, polyvinyl alcohol and dipolylactic acid-glycolic acid copolymer polyethylene glycol. The microsphere-gel combined delivery preparation PE-M / Ge prepared by the preparation method disclosed by the invention is good in injectability and has a good temperature-sensitive gelling characteristic in vitro; the obvious gel property is realized, and the microspheres are uniformly distributed in the gel; the release of the drug can be effectively reduced, the release curve is closer to zero-order release, the dual controlled release system can more stably release the drug, the toxic and side effects caused by non-characteristic distribution of PE are reduced, and the bioavailability is improved. And the PE-M / Ge has no cytotoxicity to H9c2 cells and HUVECs cells, so that a foundation is laid for in-vivo pharmacodynamic experiments of rats.

Aspects of the present disclosure provide methods, apparatuses, devices and systems for facilitating energy savings in a wireless network system, such as a user equipment (UE) centric –cell free (UC-CF) wireless system. By virtue of aspects of the present disclosure, network devices may be dynamically turned on / off so that energy usage may be effectively reduced at both the network side and the UE side without sacrificing performance. A network device may transmit information of a first set of cooperation network devices to the UE. The network device may determine at least one target network side device which belongs to the first set of cooperation network side devices. The network device may transmit, to the UE, an indication of the at least one target network device via lower layer signaling. The UE may establish a first connection with the at least one target network device.

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

Method for generating a porous injectable scaffold that includes providing a liquid composition of 2 phases at a temperature below 25° C., of Newtonian behavior, where the composition comprises:a liquid dispersant phase at room temperature formed by a gelatin with a low melting point, less than 15° C., functionalized with methacryloyl or methacrylamide groups; and a photoinitiator;and a dispersed phase, of microdroplets or beads in solid state, of a gelatin solution with a melting point greater than 25° C.;initiating the polymerization of the dispersing phase by light radiation; raising the temperature to 35-40° C. and allowing melting of the dispersed phase; and obtaining a porous scaffold.The formed porous scaffold and its use as a biological support for tissue regeneration / generation; as a biological matrix as a support for cells, for cell invasion; as an acellular biological matrix, a biological matrix as a mechanical support and / or a biological matrix for active components.

The present invention relates to a method for diagnosing cancer and predicting cancer types using a methylated cell-free nucleic acid, and more particularly, to a method for diagnosing cancer and predicting cancer types using a method for extracting methylated nucleic acids from a biospecimen, generating vectorized data of nucleic acid fragments based on aligned reads by obtaining sequence information, and then inputting the data into a trained artificial intelligence model so as to analyze a calculated value. The method for diagnosing cancer and predicting cancer types using methylated cell-free nucleic acids according to the present invention is useful because it generates vectorized data and analyzes it using an AI algorithm, compared to methods that use a conventional step of determining the amount of chromosomes based on the read count or detection methods that use the concept of distance between aligned reads to utilize values related to reads as one by one structured values, so that a similar effect can be achieved even if the read coverage is low.

The invention discloses a T7 RNA (Ribonucleic Acid) polymerase mutant, and the T7 RNA polymerase mutant comprises any one or more of the following amino acid mutation sites: W797L, P657K, Y846R, M306K, N601E, P476E, S606V, K642G, P742G, I117L, Q786L, S430P, L446F or T375K, and the T7 RNA polymerase mutant has RNA polymerase activity. The invention also discloses an application of the T7 RNA polymerase mutant in in-vitro transcription, non-coding RNA synthesis, RNA drug synthesis, in-vivo protein expression or cell-free protein expression.

The disclosure provides methods to chemically and photochemically initiate cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof, including for drug delivery, gene therapy, cell-free cell therapy, and molecular therapy.

A method of identifying a variant as a somatic variant derived from cell free DNA (cfDNA) identifies the variant at a locus based on differences between the nucleic acid sequence for a cfDNA fragment in a plurality of cfDNA fragments and a nucleic acid sequence for the locus in a reference sequence, where the cfDNA fragments are from a liquid biopsy sample from a subject. A set of cfDNA fragments comprising the variant, in the plurality of cfDNA fragments, determines fragment length metrics. A variant allele fraction (VAF) is determined based on comparison of the number of cfDNA fragments having the variant and the total number of cfDNA fragments mapping to the locus. Clonal hematopoiesis prevalence metrics for the variant are obtained. The fragment length metrics, VAF, and hematopoiesis metrics are inputted into a model thereby obtaining, as model output, whether the variant is a somatic variant derived from cfDNA.

The present disclosure includes, among other things, methods, kits, and systems for determining ER status of cancer, e.g., a breast cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of ER status of cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with cancer. In various embodiments a determined ER status is useful, e.g., in selecting treatment for and / or treating a cancer, e.g., a breast cancer.

The invention belongs to the technical field of bioinformatics, and particularly relates to a method for detecting abnormal DNA methylation fragments from cell free DNA (cell free DNA, cfDNA) and classifying the abnormal DNA methylation fragments from the cell free DNA, and the method comprises the following steps: based on a healthy cfDNA sample and a tumor cfDNA sample, selecting methylation haplotype regions (Methylation Haplotype Block, MHB) having significant difference between the two samples by adopting seven DNA methylation measurement indexes; on the basis of the selected methylated haplotype regions with significant differences, constructing total distribution of seven DNA methylation measurement indexes in the healthy cfDNA sample and the tumor cfDNA sample, and carrying out differential analysis; seven DNA methylation measurement indexes are adopted to construct classification models for abnormal DNA methylation fragments, and the classification models of the seven abnormal DNA methylation fragments are integrated on the basis of differential analysis results of overall distribution of the seven DNA methylation measurement indexes. According to the application, the abnormal DNA methylation fragments in the cell free DNA are detected by adopting seven DNA methylation measurement indexes, and the abnormal DNA methylation fragment classification model based on the seven DNA methylation measurement indexes is integrated, so that the improvement of the sensitivity of tumor early screening is facilitated.